MYGN Myriad Genetics, Inc.
Myriad Genetics, Inc. (MYGN) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.24 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.3% since its last earnings release on July 30, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Myriad Genetics, Inc.
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.
Sector
Healthcare
Industry
Medical Labs & Research